Literature DB >> 15804190

Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.

Xueqin Song1, Philip L Lorenzi, Christopher P Landowski, Balvinder S Vig, John M Hilfinger, Gordon L Amidon.   

Abstract

Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3'-Monoester, 5'-monoester, and 3',5'-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC(50): 0.14-0.16 mM) for the transporter. However, only the 5'-L-valyl and 5'-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in HeLa/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5'-L-valyl and 5'-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804190     DOI: 10.1021/mp049888e

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  32 in total

1.  Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

Authors:  Christine L Clouser; Laurent Bonnac; Louis M Mansky; Steven E Patterson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

2.  Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.

Authors:  Brian R Thompson; Jian Shi; Hao-Jie Zhu; David E Smith
Journal:  Biochem Pharmacol       Date:  2020-06-27       Impact factor: 5.858

3.  Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

Review 4.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

5.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

Review 6.  Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.

Authors:  Leslie Z Benet
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-07       Impact factor: 4.080

7.  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.

Authors:  Jing Sun; Arik Dahan; Gordon L Amidon
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

Review 9.  N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Werner Tjarks
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

10.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.